Springer SA, et al. - Whether or not extended-release naltrexone (XR-NTX) would improve or maintain viral suppression (VS) among incarcerated individuals with HIV and alcohol use disorders (AUDs) transitioning to the community was investigated. Researchers performed a randomized, double-blind, placebo-controlled trial among incarcerated individuals with HIV and AUDs transitioning to the community from 2010 through 2016. Findings revealed that VS was improved or maintained with XR-NTX among these individuals. XR-NTX as well as receipt of ≥3 injections independently predicted VS. Reductions in alcohol consumption and white race also predicted VS at <50 copies per milliliter.